DIA study links more oversight to better orphan drug access

07/30/2013 | PharmExec.com

A study sponsored by DIA found that countries with more regulatory structures for advancing treatments for rare diseases have greater access by patients to orphan drugs compared with countries with less extensive regulatory frameworks. The U.S. did not do as well as France, Spain, the U.K. and Germany in providing access to 13 orphan treatments, according to the study.

View Full Article in:

PharmExec.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC